HDAC6—An Emerging Target Against Chronic Myeloid Leukemia?

Imatinib became the standard treatment for chronic myeloid leukemia (CML) about 20 years ago, which was a major breakthrough in stabilizing the pathology and improving the quality of life of patients. However, the emergence of resistance to imatinib and other tyrosine kinase inhibitors leads researc...

Descripción completa

Detalles Bibliográficos
Autores principales: Losson, Hélène, Schnekenburger, Michael, Dicato, Mario, Diederich, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072136/
https://www.ncbi.nlm.nih.gov/pubmed/32013157
http://dx.doi.org/10.3390/cancers12020318

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072136/
https://www.ncbi.nlm.nih.gov/pubmed/32013157
http://dx.doi.org/10.3390/cancers12020318

Ejemplares similares